NetScientific PLC (AIM:NSCI) hailed "highly promising preclinical results" from portfolio company PDS Biotechnology Corporation (NASDAQ:PDSB).
In the US last night, PDS announced preclinical data for its universal flu vaccine which was shown to be effective against multiple strains of the influenza virus.
Lauren V. Wood, PDS chief medical officer, said the company is excited by the outcome.
“The COBRA antigens provide an innovative approach to generating broadly effective immune responses against influenza, which when combined with our Infectimune platform may provide effective neutralization and protection against infection,” Wood said.
“The data suggests that PDS0202, has the potential to overcome the well documented limitations faced in developing a universal influenza vaccine."
The work is being done in collaboration with Dr Jerold Woodward (NASDAQ:WWD) of the University of Kentucky College of Medicine and Dr Ted Ross from the University of Georgia.
Ross, in the statement, added: “The preclinical results show the potential for PDS0202 to be effective in preventing viral invasion of the lungs by multiple strains of the influenza virus. We look forward to seeing the PDS0202-COBRA vaccine in future human trials."
Ilian Iliev, chief executive of NetScientific added: "This preclinical data demonstrates the indicative strength of the PDS0202 vaccine, aiming to provide a highly-scalable and robust, universal vaccine for a widespread global issue.
“The data highlights the strength of PDS' innovative research, and we look forward to seeing what is in store as it progresses through clinical trials."
NetScientific owns 5.7% of PDS.